Search company, investor...


Founded Year



Acquired - II | Acquired



About Trophos

Trophos is a biopharmaceutical company developing drugs to prevent neuronal loss in patients with neurodegenerative disease. The organization has collaborative research projects on diseases such as spinal muscular atrophy (SMA), Multiple Sclerosis (MS) disability progression and Cardiac Ischemia-Reperfusion Injury (IRI).

Headquarters Location

Parc scientifique de luminy Case 931

Marseille, 13288,



Missing: Trophos's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Trophos's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Trophos Patents

Trophos has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Neuroprotective agents, Cannabinoids, Androgens and anabolic steroids, Ketones, Progestogens


Application Date


Grant Date



Related Topics

Neuroprotective agents, Cannabinoids, Androgens and anabolic steroids, Ketones, Progestogens



Latest Trophos News

Trophos s’attaque à la Sclérose en plaque – Lettre Sud Info n°814

Jun 8, 2017

Derniers Tweets #ACGManagement annonce les résultats du premier appel à projets destiné au développement des entreprises innovantes… yesterday © Copyright ACG MANAGEMENT - Conception Agence Odanak Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site. Si vous poursuivez votre navigation, nous considérerons que vous acceptez l'utilisation des cookies. Accepter En savoir plus

Trophos Frequently Asked Questions (FAQ)

  • When was Trophos founded?

    Trophos was founded in 1999.

  • Where is Trophos's headquarters?

    Trophos's headquarters is located at Parc scientifique de luminy, Marseille.

  • What is Trophos's latest funding round?

    Trophos's latest funding round is Acquired - II.

  • Who are the investors of Trophos?

    Investors of Trophos include Roche Holding, Actelion and Headway Capital Partners.

  • Who are Trophos's competitors?

    Competitors of Trophos include Oligomerix, Sound Pharmaceuticals, Longevica, BioMarck Pharmaceuticals, Bioceros and 12 more.

Compare Trophos to Competitors

Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Sound Pharmaceuticals

Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.

Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.


Hunter-Fleming is a biopharmaceutical company developing new medicines to treat neurological and cardiovascular disorders. The company focus is on unmet patient needs in dementias such as Alzheimer's disease, as well as other important conditions such as neuropathic pain, head and spinal cord injuries and myocardial infarction.


Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.